Michael Gelband’s Beam Therapeutics BEAM Stock Holding History

Michael Gelband’s Portfolio BEAM Stock Details BEAM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.09M	Buy	+89,939	New	+$2.72M	0.02%	651
2026 Q1	–	Sell	-163,316	Closed	-$4.53M	–	1566
2025 Q4	$4.53M	Buy	+163,316	New	+$4.17M	0.04%	503
2025 Q3	–	Sell	-166,055	Closed	-$2.83M	–	1536
2025 Q2	$2.83M	Buy	+166,055	New	+$2.89M	0.02%	617
2025 Q1	–	Sell	-13,359	Closed	-$331K	–	1470
2024 Q4	$331K	Buy	+13,359	New	+$341K	﹤0.01%	1250
2024 Q2	–	Sell	-8,475	Closed	-$280K	–	1535
2024 Q1	$280K	Buy	+8,475	New	+$264K	﹤0.01%	1274
2023 Q4	–	Sell	-33,781	Closed	-$812K	–	1483
2023 Q3	$812K	Buy	+33,781	New	+$906K	0.01%	1036
2022 Q2	–	Sell	-25,473	Closed	-$1.46M	–	1948
2022 Q1	$1.46M	Buy	25,473 +14,630	+135%	+$960K	0.02%	935
2021 Q4	$864K	Buy	+10,843	New	+$928K	0.01%	1152
2021 Q1	–	Sell	-15,108	Closed	-$1.23M	–	2123
2020 Q4	$1.23M	Buy	+15,108	New	+$743K	0.01%	751

Other funds holding BEAM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

AVM

Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

Michael Gelband's BEAM Position: Q2 2026 in Review

Michael Gelband opened a new position in Beam Therapeutics (BEAM) in Q2 2026: 89,939 shares worth $3.09M. The stake represents 0.02% of the portfolio and ranks #651 among its holdings. This is a return to the name: Michael Gelband previously reported a position in BEAM as recently as Q4 2025.

Michael Gelband first reported a position in BEAM in Q4 2020 and has held it in 9 quarters since. The position peaked at $4.53M in Q4 2025. 275 funds tracked by Wall St. Rank hold BEAM as of Q2 2026.

Michael Gelband held 89,939 shares of Beam Therapeutics worth $3.09M as of Q2 2026.
Beam Therapeutics was a new Michael Gelband position in Q2 2026.
Beam Therapeutics made up 0.02% of Michael Gelband's portfolio in Q2 2026, its #651 holding.
Michael Gelband first reported a position in Beam Therapeutics in Q4 2020 and has held it in 9 quarters since.
Michael Gelband's Beam Therapeutics position peaked at $4.53M in Q4 2025.
275 funds tracked by Wall St. Rank held Beam Therapeutics as of Q2 2026.

Based on ExodusPoint Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.